Table 1.
Disclosure of conflicts of interest and potential conflicts of interest with core companies (PTEC_COsa)
| Total | Conflicts of interest disclosure status | Potential conflicts of interest with core companiesb | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No disclosure (code 0 ) | Disclosed no COIs (code 1 ) | Disclosed COIs for previous studies or for some authors (code 2 ) | Disclosed no COIs, but acknowledge financial support by PTEC_COsa (code 3 ) | Disclosed potential COIs (code 4 ) | Pharmaceutical companies | Tobacco companies | E-cigarette companies | ||
| n | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| All publications | 404 | 150 (37.1) | 156 (38.6) | 25 (6.2) | 18 (4.5) | 55 (13.6) | 54 (13.4) | 12 (3.0) | 43 (10.6) |
| Type of publication | |||||||||
| Original article | 149 | 34 (22.8) | 65 (43.6) | 13 (8.7) | 12 (8.1) | 25 (16.8) | 24 (16.1) | 4 (2.7) | 23 (15.4) |
| Review | 44 | 11 (25.0) | 18 (40.9) | 4 (9.1) | 2 (4.5) | 9 (20.5) | 10 (22.7) | 4 (9.1) | 4 (9.1) |
| Editorial | 25 | 16 (64.0) | 8 (32.0) | 0 (0.0) | 0 (0.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Letter | 35 | 7 (20.0) | 19 (54.3) | 1 (2.9) | 1 (2.9) | 7 (20.0) | 5 (14.3) | 1 (2.9) | 8 (22.9) |
| News | 42 | 42 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Commentary | 20 | 2 (10.0) | 10 (50.0) | 4 (20.0) | 1 (5.0) | 3 (15.0) | 6 (30.0) | 1 (5.0) | 3 (15.0) |
| Other | 89 | 38 (42.7) | 36 (40.4) | 3 (3.4) | 2 (2.2) | 10 (11.2) | 9 (10.1) | 2 (2.2) | 5 (5.6) |
| Languagec | |||||||||
| English | 388 | 140 (36.1) | 152 (39.2) | 24 (6.2) | 18 (4.6) | 54 (13.9) | 52 (13.4) | 12 (13.1) | 42 (10.8) |
| Other | 16 | 10 (62.5) | 4 (25.0) | 1 (6.3) | 0 (0.0) | 1 (6.3) | 2 (12.5) | 0 (0.0) | 1 (6.3) |
| Continent of first author | |||||||||
| North Americad | 205 | 61 (29.8) | 107 (52.2) | 4 (2.0) | 14 (6.8) | 19 (9.3) | 14 (6.8) | 4 (2.0) | 5 (2.4) |
| Africa | 4 | 3 (75.0) | 1 (25.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (25.0) |
| Asia | 12 | 8 (66.7) | 4 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Europe | 137 | 46 (33.6) | 36 (26.3) | 20 (14.6) | 3 (2.2) | 32 (23.4) | 36 (26.3) | 7 (5.1) | 32 (23.4) |
| Oceania | 15 | 3 (20.0) | 6 (40.0) | 1 (6.7) | 1 (6.7) | 4 (26.7) | 4 (26.7) | 1 (6.7) | 5 (33.3) |
| Unknown | 31 | 29 (93.5) | 2 (6.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0) |
| Main topic | |||||||||
| Prevalence | 43 | 14 (32.6) | 16 (37.2) | 2 (4.7) | 4 (9.3) | 7 (16.3) | 5 (11.6) | 1 (2.3) | 3 (7.0) |
| Toxicology | 53 | 22 (41.5) | 12 (22.6) | 4 (7.5) | 4 (7.5) | 11 (20.8) | 7 (13.2) | 1 (1.9) | 10 (18.9) |
| Health effects | 39 | 9 (23.1) | 19 (48.7) | 3 (7.7) | 2 (5.1) | 6 (15.4) | 5 (12.8) | 2 (5.1) | 9 (23.1) |
| Smoking cessation | 44 | 10 (22.7) | 16 (36.4) | 5 (11.4) | 1 (2.3) | 12 (27.3) | 16 (36.4) | 2 (4.5) | 10 (22.7) |
| Topography | 3 | 0 (0.0) | 3 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Attitudes, knowledge | 22 | 7 (31.8) | 10 (45.5) | 2 (9.1) | 1 (4.5) | 2 (9.1) | 3 (13.6) | 1 (4.5) | 0 (0.0) |
| Regulation, marketing | 99 | 46 (46.5) | 44 (44.4) | 3 (3.0) | 2 (2.0) | 4 (4.0) | 3 (3.0) | 0 (0.0) | 4 (4.0) |
| Clinical advice | 3 | 1 (33.3) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 1 (33.3) | 0 (0.0) | 0 (0.0) |
| Other | 11 | 3 (27.3) | 6 (54.5) | 0 (0.0) | 1 (9.1) | 1 (9.1) | 0 (0.0) | 1 (9.1) | 0 (0.0) |
| Miscellaneous | 87 | 38 (43.7) | 29 (33.3) | 6 (6.9) | 3 (3.4) | 11 (12.6) | 14 (16.1) | 4 (4.6) | 7 (8.0) |
| Empirical data | |||||||||
| Yes | 166 | 37 (22.3) | 77 (46.4) | 13 (7.8) | 12 (7.2) | 27 (16.3) | 25 (15.1) | 5 (3.0) | 25 (15.1) |
| No | 238 | 113 (47.5) | 79 (33.2) | 12 (5.0) | 6 (2.5) | 28 (11.8) | 29 (12.2) | 7 (2.9) | 18 (7.6) |
| Main subjecte (n=166) | |||||||||
| Humans | 103 | 20 (19.4) | 46 (44.7) | 7 (6.8) | 9 (8.7) | 21 (20.4) | 20 (19.4) | 4 (3.9) | 19 (18.4) |
| E-cigarettes per se | 37 | 12 (32.4) | 15 (40.5) | 3 (8.1) | 2 (5.4) | 5 (13.5) | 4 (10.8) | 1 (2.7) | 5 (13.5) |
| Regulation, marketing | 19 | 3 (15.8) | 13 (68.4) | 2 (10.5) | 0 (0.0) | 1 (5.3) | 1 (5.3) | 0 (0.0) | 1 (5.3) |
| Otherf | 7 | 2 (28.6) | 3 (42.9) | 1 (14.3) | 1 (14.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
a
PTEC_COs: pharmaceutical (P), tobacco (T) and/or electronic cigarette (EC) companies.
b
Potential conflicts of interest with core companies are not exclusive.
c
There was 1 publication in both English and French that was codified as an English language publication.
d
All publications were from the United States or Canada.
e
Publications with empirical data only.
f
Other subjects: in vitro studies, animal studies, or other.